RP3

Oncolytic virus

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2023-12), as a strategic decision by the sponsor

Replimune stopped RP3 to focus on its RP1 and RP2 priority studies after CERPASS. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Other / comorbidity
NCT05743270 · Replimune, Inc.
2024-01-30 – 2026-06-01 · Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT05733611 · Replimune, Inc.
2023-06-29 – 2025-08-18 · Refractory Metastatic Colorectal Cancer, pMMR, MSS
What this study did
Phase 1 (1)
Other / comorbidity

Competitive landscape

Other Tumor cells (oncolytic replication) drugs

Pelareorep. Compare all 2 Tumor cells (oncolytic replication) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Solid Tumors: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RP3: this drugDiscontinuedOncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Weak signalNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETnot yet gradedNo reviewed efficacy summary in this indication
Pelareorep
Phase 2(overall)
Oncolytic virusTumor cells (oncolytic replication)
not yet graded(overall)
No reviewed efficacy summary in this indication
ALG.APV-527Phase 1/2Multispecific antibody4-1BB (CD137) x 5T4not yet gradedNo reviewed efficacy summary in this indication
CR-001
Phase 1/2(overall)
Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cell therapyTumor antigen menu (TROP2, MSLN, B7-H3, HER2)not yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Single-Target CAR-NK CellsPhase 1/2Cell therapyPersonalized, biomarker-guided allogeneic chimeric antigen receptornot yet gradedNo reviewed efficacy summary in this indication
Micvotabart PelidotinPhase 1/2Antibody–drug conjugateED-B domain of fibronectinnot yet gradedNo reviewed efficacy summary in this indication
Linebacker
—(overall)
Small moleculePIM kinases (PIM1/2/3)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.